Breaking News

You are here » Indian-Commodity  :  Corporate  :  AstraZeneca Pharma receives Marketing Authorization from DCGI

18-Oct2017

AstraZeneca Pharma receives Marketing Authorization from DCGI

AstraZeneca Pharma India has received Import and Market Permission in Form 45 (Marketing Authorization) from the Drug Controller General of India (DCGI) for FDC of Dapagliflozin + Metformin Hydrochloride (Extended Release) film coated tablets (XIGDUO XR).

The FDC of Dapagliflozin + Metformin Hydrochloride (Extended Release) film coated tablets (XIGDUO XR) is indicated as an ajunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both dapagliflozin and metformin is appropriate.

AstraZeneca Pharma India is a global biopharmaceutical company. The company is engaged in the discovery, development and commercialization of medicines for core areas of healthcare, including cardiovascular/metabolic disease, cancer and respiratory, inflammatory and autoimmune disease. The company operates through two segments Healthcare and Clinical Trial.



Related News

View all news

Gujarat Petrosynthese to invest surplus funds in mutual funds, bonds, securities, shares

Gujarat Petrosynthese has received an approval to invest surplus funds in mutual funds, bonds, securities, shares, inter corporate deposits etc. to optimize its returns. The Board of Directors of the Company......

Reliance's Retail Unit delivers record-breaking performance in revenue, profits during FY19

Reliance Industries' Retail Unit--Reliance Retail has delivered a record-breaking performance in revenue and profits growth for the year 2018-19. Segment Revenue for FY19 grew by 88.7% Y-o-Y to Rs 130,566......

Tata Sponge Iron reports 48% fall in Q4 consolidated net profit

Tata Sponge Iron has reported results for fourth quarter and year ended March 31, 2019.The company has reported a fall of 47.82% in its net profit at Rs 24.37 crore for the quarter under review as compared......

Top News

View all news

Bank of Baroda's board to consider issuance of equity shares of Rs 5,042 crore to Govt

Bank of Baroda's board is going to consider issuance of equity shares of Rs 5,042 crore to Government of India on a Preferential Basis. The meeting of the Board of Directors of the Bank is scheduled to......

Gujarat Petrosynthese to invest surplus funds in mutual funds, bonds, securities, shares

Gujarat Petrosynthese has received an approval to invest surplus funds in mutual funds, bonds, securities, shares, inter corporate deposits etc. to optimize its returns. The Board of Directors of the Company......

Reliance's Retail Unit delivers record-breaking performance in revenue, profits during FY19

Reliance Industries' Retail Unit--Reliance Retail has delivered a record-breaking performance in revenue and profits growth for the year 2018-19. Segment Revenue for FY19 grew by 88.7% Y-o-Y to Rs 130,566......